

MARKSANS PHARMA LIMITED

Regd. Office: 601-622, Chintamani Plaza, Mohan Studio Compd, A.K.Road, Andheri [East], Mumbai-400099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2006

(Rs. In lacs)

Sr. No.	PARTICULARS	Quarter ended		six months ended		Year ended
		30th Sept. 06 (UNAUDITED)	30th Sept. 05 (UNAUDITED)	30th Sept. 06 (UNAUDITED)	30th Sept. 05 (UNAUDITED)	31st March 06 (AUDITED)
1	Net sales /Income from Operations	7,139.70	8,984.40	14,184.54	17,474.17	29,185.45
2	Other Income	369.61	39.84	644.87	79.83	471.17
3	Total Expenditure	6,203.11	7,299.26	12,333.16	14,220.79	24,685.36
	-(Increase) /Decrease in Stock in trade	(212.18)	(142.19)	(644.85)	574.95	(2,355.44)
	-Consumption of Raw Material	5,174.51	6,294.15	10,574.73	11,428.54	22,648.37
	-Staff Cost	295.07	160.38	517.33	353.40	947.11
	-Other Expenditure	945.71	986.92	1,885.95	1,863.90	3,445.32
4	Interest	273.64	265.06	527.59	587.62	1,035.08
5	Depreciation	323.44	378.08	536.63	553.54	803.98
6	Profit/(Loss) before Ta	709.12	1,081.84	1,432.03	2,192.05	3,132.20
7	Provision for Taxation	125.00	44.18	270.00	151.91	814.24
8	Net Profit /(Loss)	584.12	1,037.66	1,162.03	2,040.14	2,317.96
9	Add/Less :Short provision/ Prior period expenses					29.53
10	Net Profit/(after extra ordinary items	584.12	1,037.66	1,162.03	2,040.14	2,288.43
11	Paid up Equity Share Capital (Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus (Excluding Revaluation Reserve)	-	-	-	-	5,286.46
13	Basic and Diluted EPS for the period (Not annualised)	1.63	2.89	3.23	5.68	6.37
14	Non -Promoter share holding					
	-Number of Shares	18778527	18340527	18778527	18340527	18778569
	-Percentage of Share holding	52.25%	51.03%	52.25%	51.03%	52.25%

Notes:

- The above results were taken on records at the Board meeting held on 30-10-2006
- The details of investor complaints during the quarter is as under:
Opening Balance : NIL, Received during the quarter : 2, Pending as on 30.09.06 : NIL
- The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For Marksans Pharma Limited

Place: Mumbai

Date: 30th October, 2006

Mark Saldanha
Managing Director